Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Director/PDMR Shareholding

1st Apr 2009 12:00

Director/PDMR Shareholding

April 1, 2009 - Shire plc , the global specialty biopharmaceutical company, announces that on April 1, 2009 the trustee of the Shire Employee Benefit Trust (the "Trust") informed the Company that, on March 31, 2009, the following Ordinary Shares and ADSs had been allocated under the Shire Executive Annual Incentive Plan (the "Plan") to the Executive Directors and Persons Discharging Managerial Responsibility set out below. The Ordinary Shares were bought on the market on March 31, 2009 at a price of £8.5361 per share and the ADSs were bought on the same date at a price of US$36.8794 per ADS. The allocations are in respect of performance in 2008.

Name of Director Type of Security Number Angus Russell Ordinary Shares 37,814 Graham Hetherington Ordinary Shares 9,007 Name of PDMR Type of Security Number Michael Cola ADSs 6,374 Barbara Deptula ADSs 4,902 Anita Graham ADSs 4,132 Sylvie Gregoire ADSs 5,631 Tatjana May Ordinary Shares 14,010 Joseph Rus Ordinary Shares 11,708

Under the terms of the Plan the Ordinary Shares and ADSs will not normally be released to participants for three years.

This notification relates to disclosures made in accordance with 3.1.4(R)(1)(a) of the Disclosure and Transparency Rules.

Tony GuthrieDeputy Company Secretary

For further information please contact:

Investor Relations Cl©a Rosenfeld (Rest of the World) +44 1256 894 160 Eric Rojas (North America) +1 617 551 9715 Notes to editorsSHIRE PLC

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's website: www.shire.com.

Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PXPress Release

www.shire.com

vendor

Related Shares:

Shire
FTSE 100 Latest
Value8,774.65
Change-17.15